Answers are grounded in this paper and cite their sources.
Epithelial-derived intelectin-1 (ITLN1) is frequently downregulated in colorectal cancer, but whether it actively shapes anti-tumor immunity remains unclear. We integrate multiplex immunohistochemistry, spatial analysis, single-cell transcriptomics, chromatin-accessibility profiling, and perturbation models to define how ITLN1 regulates neutrophil maturation and spatial anti-tumor immunity. In treatment-naïve human colorectal cancer, higher ITLN1 expression associates with greater neutrophil infiltration, shorter distances between mature S100A9 + CXCR2 + neutrophils and ITLN1 + tumor epithelial cells, and improved survival. In mouse colorectal cancer models, Itln1 silencing accelerates tumor growth and metastasis, impairs CXCR2 + CD101 + mature neutrophil generation and tumor recruitment, and promotes LTF + S100A9 + immature neutrophil accumulation in hypoxic regions. Mechanistically, ITLN1 activates a JAK1/STAT3-associated C/EBPδ program that drives terminal granulopoiesis and CXCR2-dependent tumor homing, while recombinant ITLN1 restores neutrophil maturation and tumor-killing activity. Here, we reveal a cross-tissue ITLN1–STAT3/C/EBPδ–CXCR2 axis that links epithelial ITLN1 to bone marrow granulopoiesis, coordinating distal neutrophil maturation, mobilization and spatial organization in colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: